Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

HeartSciences (HSCS) Equity Average (2021 - 2026)

HeartSciences filings provide 6 years of Equity Average readings, the most recent being $3.4 million for Q1 2026.

  • On a quarterly basis, Equity Average rose 17.77% to $3.4 million in Q1 2026 year-over-year; TTM through Jan 2026 was $3.4 million, a 17.77% increase, with the full-year FY2025 number at $3.8 million, changed 0.34% from a year prior.
  • Equity Average hit $3.4 million in Q1 2026 for HeartSciences, down from $3.7 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $8.0 million in Q2 2024 to a low of -$5.1 million in Q2 2022.
  • Median Equity Average over the past 5 years was $1.7 million (2025), compared with a mean of $1.6 million.
  • Biggest five-year swings in Equity Average: tumbled 154.65% in 2023 and later surged 58411.6% in 2024.
  • HeartSciences' Equity Average stood at $2.0 million in 2022, then plummeted by 154.65% to -$1.1 million in 2023, then skyrocketed by 558.69% to $5.0 million in 2024, then fell by 26.4% to $3.7 million in 2025, then dropped by 6.68% to $3.4 million in 2026.
  • The last three reported values for Equity Average were $3.4 million (Q1 2026), $3.7 million (Q4 2025), and $1.7 million (Q3 2025) per Business Quant data.